BioMarin Plans FDA Submission After Positive VOXZOGO Hypochondroplasia Trial

BioMarin’s VOXZOGO improved growth in children with hypochondroplasia, showing strong trial results and good safety.

BioMarin Plans FDA Submission After Positive VOXZOGO Hypochondroplasia Trial
Credit: Carsten Snejbjerg/Bloomberg
Already have an account? Sign in.